{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T13:08:43Z","timestamp":1779023323983,"version":"3.51.4"},"reference-count":58,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":243,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.csbj.2021.08.052","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:11:05Z","timestamp":1630548665000},"page":"4997-5007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A quantitative systems pharmacology model for acute viral hepatitis B"],"prefix":"10.34133","volume":"19","author":[{"given":"Eduardo","family":"As\u00edn-Prieto","sequence":"first","affiliation":[{"name":"Pharmacometrics & Systems Pharmacology Lab, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, C\/Irunlarrea 1, University of Navarra, Pamplona 31080, Spain"},{"name":"IdiSNA, Navarra Institute for Health Research, C\/Irunlarrea 3, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinnia P.","family":"Parra-Guillen","sequence":"additional","affiliation":[{"name":"Pharmacometrics & Systems Pharmacology Lab, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, C\/Irunlarrea 1, University of Navarra, Pamplona 31080, Spain"},{"name":"IdiSNA, Navarra Institute for Health Research, C\/Irunlarrea 3, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 David","family":"G\u00f3mez Mantilla","sequence":"additional","affiliation":[{"name":"Pharmacometrics & Systems Pharmacology Lab, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, C\/Irunlarrea 1, University of Navarra, Pamplona 31080, Spain"},{"name":"IdiSNA, Navarra Institute for Health Research, C\/Irunlarrea 3, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris","family":"Vandenbossche","sequence":"additional","affiliation":[{"name":"Global Clinical Pharmacology, Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Stuyckens","sequence":"additional","affiliation":[{"name":"Global Clinical Pharmacology, Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier Woot","family":"de Trixhe","sequence":"additional","affiliation":[{"name":"Global Clinical Pharmacology, Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Perez-Ruixo","sequence":"additional","affiliation":[{"name":"Global Clinical Pharmacology, Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1aki F.","family":"Troconiz","sequence":"additional","affiliation":[{"name":"Pharmacometrics & Systems Pharmacology Lab, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, C\/Irunlarrea 1, University of Navarra, Pamplona 31080, Spain"},{"name":"IdiSNA, Navarra Institute for Health Research, C\/Irunlarrea 3, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"221","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection","volume":"319","author":"Tang L.S.Y.","year":"2018","unstructured":"Tang L.S.Y., Covert E., Wilson E. and Kottilil S.: Chronic hepatitis B infection. JAMA 2018; 319: 1802.","journal-title":"JAMA"},{"key":"e_1_3_5_3_2","unstructured":"World Health Organization. (2018) Hepatitis B \u2013 Fact sheet Available from: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29323"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"e0156667","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab M.","year":"2016","unstructured":"Al-Mahtab M., Bazinet M., Vaillant A. and Su C.-W.: Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS ONE 2016; 11: e0156667.","journal-title":"PLoS ONE"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection NaIve to Nucleos(t)ide Therapy","volume":"158","author":"Bazinet M.","year":"2020","unstructured":"Bazinet M., P\u00e2ntea V., Placinta G., Moscalu I., Cebotarescu V. et al: Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection NaIve to Nucleos(t)ide Therapy. Gastroenterology 2020; 158: 2180.","journal-title":"Gastroenterology"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27805"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.4254\/wjh.v7.i21.2319","article-title":"Innate immune recognition of hepatitis B virus","volume":"7","author":"Liu H.Y.","year":"2015","unstructured":"Liu H.Y. and Zhang X.Y.: Innate immune recognition of hepatitis B virus. World J Hepatol. 2015; 7: 2319.","journal-title":"World J Hepatol."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.07.009"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.04.031"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80295-2"},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00258","article-title":"The Role of Natural Killer Cells and CD8+ T Cells in Hepatitis B Virus Infection","volume":"5","author":"Schuch A.","year":"2014","unstructured":"Schuch A., Hoh A. and Thimme R.: The Role of Natural Killer Cells and CD8+ T Cells in Hepatitis B Virus Infection. Front Immunol 2014; 5: 1.","journal-title":"Front Immunol"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/cmi.2017.132","article-title":"Humoral immunity, the underestimated player in hepatitis B","volume":"15","author":"Zhang S.","year":"2018","unstructured":"Zhang S., Zhao J. and Zhang Z.: Humoral immunity, the underestimated player in hepatitis B. Cell Mol Immunol 2018; 15: 645.","journal-title":"Cell Mol Immunol"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20649"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4049\/jimmunol.177.1.739","article-title":"Circulating and liver resident CD4+CD25+ regulatory T Cells actively influence the antiviral immune response and disease progression in patients with hepatitis B","volume":"177","author":"Xu D.","year":"2006","unstructured":"Xu D., Fu J., Jin L., Zhang H., Zhou C., Zou Z. et al: Circulating and liver resident CD4+CD25+ regulatory T Cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739.","journal-title":"J Immunol"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2017.05.003"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","article-title":"Viral dynamics in hepatitis B virus infection","volume":"93","author":"Nowak M.A.","year":"1996","unstructured":"Nowak M.A., Bonhoeffer S., Hill A.M., Boehme R., Thomas H.C. and McDade H.: Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603626104"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2007.02.017"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003730"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039591"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2018.03.025"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/app6080219"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00285-010-0397-x"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-5193(05)80142-0","article-title":"Mathematical model of antiviral immune response. I. Data analysis, generalized picture construction and parameters evaluation for hepatitis B","volume":"151","author":"Marchuk G.I.","year":"1991","unstructured":"Marchuk G.I., Petrov R.V., Romanyukha A.A. and Bocharov G.A.: Mathematical model of antiviral immune response. I. Data analysis, generalized picture construction and parameters evaluation for hepatitis B. J Theor Biol 1991; 151: 1.","journal-title":"J Theor Biol"},{"key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1752-0509-7-95","article-title":"The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models","volume":"7","author":"Palsson S.","year":"2013","unstructured":"Palsson S., Hickling T.P., Bradshaw-Pierce E.L., Zager M., Jooss K., O\u2019Brien P.J. et al: The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models. BMC Syst Biol 2013; 7: 95.","journal-title":"BMC Syst Biol"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.05.017"},{"key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-540-29604-1","volume-title":"Physics of the Human Body","author":"Herman I.P.","year":"2007","unstructured":"Herman I.P.: Terminology, the standard human, and scaling physics of the human body. In: Physics of the Human Body. Berlin: Springer 2007: 1."},{"key":"e_1_3_5_30_2","unstructured":"Sharma R Sharma S. Physiology Blood Volume In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2019."},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0300-9629(82)90205-5"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050377"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.260539"},{"key":"e_1_3_5_34_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4149\/av_2013_04_421","article-title":"Vector-mediated expression of interferon gamma inhibits replication of hepatitis B virus in vitro","volume":"57","author":"Kan Q.C.","year":"2013","unstructured":"Kan Q.C., Li D.L. and Yu Z.J.: Vector-mediated expression of interferon gamma inhibits replication of hepatitis B virus in vitro. Acta Virol 2013; 57: 421.","journal-title":"Acta Virol"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2011.12.016"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902761"},{"key":"e_1_3_5_37_2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1537-2995.2008.01701.x","article-title":"Hepatitis B virus infection and transfusion medicine: science and the occult","volume":"48","author":"Hollinger F.B.","year":"2008","unstructured":"Hollinger F.B.: Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008; 48: 1001.","journal-title":"Transfusion"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10291"},{"key":"e_1_3_5_39_2","doi-asserted-by":"crossref","unstructured":"Whalley SA Murray JM Brown D Webster GJM Emery VC et al. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 2001;193(7):847\u2013853.","DOI":"10.1084\/jem.193.7.847"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22881"},{"key":"e_1_3_5_41_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1423-0410.2005.00602.x","article-title":"Hepatitis B NAT virus-positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA","volume":"88","author":"Yoshikawa A.","year":"2005","unstructured":"Yoshikawa A., Gotanda Y., Itabashi M., Minegishi K., Kanemitsu K. and Nishioka K.: Hepatitis B NAT virus-positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005; 88: 77.","journal-title":"Vox Sang"},{"key":"e_1_3_5_42_2","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1537-2995.2007.01234.x","article-title":"Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage","volume":"47","author":"Yoshikawa A.","year":"2007","unstructured":"Yoshikawa A., Gotanda Y., Minegishi K., Taira R., Hino S., Tadokoro K. et al: Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion 2007; 47: 1162.","journal-title":"Transfusion"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2013.14"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015324"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0401771101"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.163600"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.06.054"},{"key":"e_1_3_5_48_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3748\/wjg.v13.i1.82","article-title":"Pathogenesis of hepatitis B virus infection","volume":"13","author":"Baumert T.F.","year":"2007","unstructured":"Baumert T.F., Thimme R. and von Weizs\u00e4cker F.: Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13: 82.","journal-title":"World J Gastroenterol"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.1.68-76.2003"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00264-1"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316644"},{"key":"e_1_3_5_52_2","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1128\/JVI.79.6.3322-3328.2005","article-title":"Modulation of the CD8 + -T-Cell response by CD4 + CD25 + regulatory T cells in patients with hepatitis B virus infection","volume":"79","author":"Franzese O.","year":"2005","unstructured":"Franzese O., Kennedy P.T.F., Gehring A.J., Gotto J., Williams R., Maini M.K. et al: Modulation of the CD8 + -T-Cell response by CD4 + CD25 + regulatory T cells in patients with hepatitis B virus infection. J Virol 2005; 79: 3322.","journal-title":"J Virol"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.3390\/v9050095"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.06.016"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.3390\/v12070746"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3856"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms16023307"},{"key":"e_1_3_5_58_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3748\/wjg.v22.i1.145","article-title":"Overview of hepatitis B virus mutations and their implications in the management of infection","volume":"22","author":"Caligiuri P.","year":"2016","unstructured":"Caligiuri P., Cerruti R., Icardi G. and Bruzzone B.: Overview of hepatitis B virus mutations and their implications in the management of infection. World J Gastroenterol 2016; 22: 145.","journal-title":"World J Gastroenterol"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.19324"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037021003834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037021003834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2021.08.052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T12:50:24Z","timestamp":1779022224000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2021.08.052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":58,"alternative-id":["10.1016\/j.csbj.2021.08.052"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2021.08.052","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A quantitative systems pharmacology model for acute viral hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2021.08.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}